Exchange: NASDAQ·Updated 07:30 PM EST
AVR logo

AVR Anteris Technologies Global

$5.09
$0.10
(1.97%)
Today
Closed $4.99
$0.10
(2.00%)
After Hours
Reported EarningsNov 10
Mkt Cap$486.49M
Vol1.54M

About AVR

Anteris Technologies Global Corp. is a structural heart company, which engages in the development and commercialization of medical devices for heart diseases. It operates through the following geographical segments: United States, Germany, Australia, Switzerland, and Sweden. The company was founded in 1999 and is headquartered in Eagan, MN.
56

Bullish Sentiment

How do you feel about AVR?

Idvst8
$AVR - For those who have a time horizon, beyond a few weeks, this is a very attractive level. May see $4 handle on macro market erotion.......but this puppy is a great Spec Play
1
6
gassedprowler
$AVR these results confirm the hemodynamic advantage of durAVR is durable to 1 year and that safety is in line with competitors. The real differentiator is the 1% heart failure hospitalization rate. If that finding translates at scale in PARADIGM we could see a significantly lower primary composite endpoint. Better flow (laminar) results in better LV mass regression and remodeling which results in a lower heart failure hospitalization rate. Hospitals will be willing to add a superior device to their inventory if it prevents further hospitalizations and will even pay a premium for it. durAVR has a lower new pacemaker rate than $MDT Evolut which also saves them money and the patient another procedure.
5
TitanMoonofSaturn
$AVR Mark this post. Deal of a lifetime: you're getting shares pried from the sweaty hands of funds forced to de-gross. Selling has nothing to do with the data. Fidelity's adding, L1 bought back, the specialists are holding. Someone's handing you their shares at the bottom Medtronic, L1, fidelity; Sio and blackrock own 49% of the company. Just 5 institutions own that much $SPY $IHI $MDT $XBI
8
TitanMoonofSaturn
$AVR Medium DurAVR numbers just dropped and honestly they're better than the small. 22 patients, 30 days. EOA 2.64, gradient 6.2, nobody with moderate or severe mismatch, nobody with moderate or severe leak, zero valve deaths. Annulus avg 492. Here's what I like most: the small did 2.2 in a 404 annulus, the medium did 2.64 in a 492. Same efficiency per mm² going up a size. Bigger anatomy didn't make it look good, the valve held its edge. For context, a Sapien 26 in that range usually lands somewhere around 1.7–1.9 with gradients in the low teens. DurAVR is posting self-expander-type flow with a balloon-expandable deployment. Docs have wanted both in one valve for years. Small + Medium together cover the bulk of TAVR patients, roughly 70–80%. The medium's going into PARADIGM now, cash is good, and the CEO's new stock awards don't fully vest until $61.50. Edwards runs a $52B market cap, mostly on TAVR. Anteris is around $600M. Something doesn't add up. $EW $MDT $BSX
1
5
gassedprowler
$AVR reviewed the slides from today. Here are the highlights. Medium DurAVR data are about as clean as you could ask for. 22 pts, mean annulus 492 mm² / 24.8 mm. 30-day hemodynamics: • Mean gradient: 6.17 mmHg • EOA: 2.64 cm² • DVI: 0.59 • 0% moderate/severe PVL • 100% insignificant PPM Safety: • 0 strokes • 0 MI • 0 major vascular complications • 0 significant bleeding • Pacemaker: 1/22 (4.5%) • No device-related surgery/intervention Most important to me: the medium valve basically reproduces the small-valve phenotype. Small → Medium: Gradient 8.2 → 6.17 EOA 2.2 → 2.64 DVI 0.60 → 0.59 That last line matters. DVI stayed essentially identical as DurAVR moved into a much larger annulus. The bear case that DurAVR’s hemodynamic advantage was mainly a small-annulus phenomenon just got harder to defend. Still only n=22 and single-arm, so PARADIGM is what matters. But the signal is becoming remarkably consistent across valve sizes. The biomimetic design appears to scale.
7
Templar57
$AVR Yesterday, Cantor Fitzgerald reiterated its price target of $15. CANTOR separately estimates Q1 2027 for PARADIGM full enrollment, giving us a specific milestone to track
5
Templar57
$AVR Reported institutional holdings rose 6.6% to 70.2 million AVR shares, an increase of 4.37 million. Against roughly 97.5 million shares outstanding, that represents approximately 72% ownership. The disconnect today is the gap between encouraging early results and the pivotal data needed to validate them. I see asymmetric upside from several potential advantages working together: • Larger effective orifice area (EOA) • Less prosthesis-patient mismatch (PPM) • Lower permanent pacemaker rates • Fewer hospitalizations within 30 days • Lower mortality and stroke rates • Favorable valve-in-valve options • Greater left ventricular mass regression • Improved durability If confirmed, those benefits could strengthen adoption, expand the addressable market into younger patients, and reduce the need for repeat interventions over their lifetimes. That combination is what drives my long-term thesis.
5
gassedprowler
$AVR These are images from Dr. Garcia’s Case in a Box presentation from TCT on 11/3. Look at the closed valves (diastole) DurAVR is in the middle. You can trace the Y where its biomimetic molded leaflets meet. Now follow the blue line as DurAVR opens. DurAVR opens rapidly and holds a wider opening through systole. Peak geometric opening area was roughly 3.0 cm² for DurAVR, 2.6 for Evolut FX+ and 2.1 for SAPIEN UR. The power curve adds something a still image can’t show. Power is work per second. DurAVR’s initial peak is higher than SAPIEN’s, but its power drops sharply once open. Add up the area under each power curve and DurAVR has the lowest total work over the measured interval. Reading from the graph, that’s about 0.043 joules for DurAVR, 0.064 for SAPIEN and 0.071 for Evolut. A valve that lets the LV eject the same volume against a lower gradient reduces the work the ventricle does each beat. This is why I expect to see faster/greater LV mass regression in durAVR patients.
5
TitanMoonofSaturn
$AVR $ABT digging into where Abbott actually is with its balloon-expandable TAVR, and the gap vs Anteris is bigger than I expected. Abbott did its first implants in Nov 2024. Its US feasibility study is 11 patients & there's no pivotal announced. On the Q3 call Ford just said "we've got a balloon expandable TAVR valve going in" with no timeline. Anteris is already enrolling a 1k patient pivotal across the US/Europe. FDA signed off on it a year ago. Feasibility to pivotal to readout takes years. Anteris is through the steps Abbott hasn't started. What jumped out: same doctors on both. Latib & Bapat did Abbott's first cases and are core to DurAVR. Kodali led DurAVR's first-in-human paper and is presenting Abbott's data Sunday. They go back to back at TCT on Nov 1. DurAVR's first medium-size data at 11:06, Abbott at 11:13. Duravr data first Building is Abbott's call. Buying would be a lot faster and smarter, I am not saying they will acquire but they have an appetite for the product.
5
Orlandotrader
$AVR Small annuli are the hardest test in TAVR, and these patients were symptomatic, with 61% in NYHA class III or IV at baseline. At one year, heart failure hospitalization was just 1%, a fraction of the rate typically observed after valve replacement. The cardiac MRI data show why DurAVR is different: with single-digit gradients and no moderate or severe paravalvular leak, left ventricular mass regressed by 24%, which tells us the heart is unloading and beginning to remodel. We believe DurAVR's biomimetic design and its potential to restore more physiologic blood flow may contribute to improved cardiac remodeling. These findings are consistent with that hypothesis, and PARADIGM is designed to test DurAVR head-to-head against today's commercial valves. These results give us strong conviction going into the pivotal trial," said Chris Meduri, MD, MPH, Chief Medical Officer of Anteris.
2
Templar57
$AVR We’re entering a phase where each clinical milestone can reduce uncertainty and change how investors value Anteris. The path may be bumpy, but I think the opportunity is in taking a measured risk before the market has the benefit of clearer data.
4
BIOTECH_GURU
$AVR i don't think this is a spec play at all. They are implanting valves in oatients today and have excellent hemodynamic data that has been presented.n
2
focafoca99
$AVR posted 30-day results for its DurAVR heart valve, showing single-digit gradients and no valve-related mortality.
3
AlertsAndNews
$AVR Anteris Reports Medium-Size DurAVR THV Outcomes from the EMBARK Study at TCT 2026 "The DurAVR THV demonstrated single digit mean gradients, large effective orifice areas (EOAs), no moderate or severe paravalvular leaks and no valve related mortality, with 100% freedom from moderate or severe prosthesis-patient mismatch* (PPM) in a cohort of medium annuli patients from the EMBARK Study."
3
Orlandotrader
$AVR Cardiac remodeling: In a cardiac magnetic resonance (CMR) substudy (n = 64), left ventricular (LV) mass, a marker of modifying the underlying disease, regressed by 24% at 1 year. LV mass in the patients evaluated was similar to that reported in matched controls without aortic valve disease3. These findings are consistent with sustained unloading of the left ventricle.
1
Orlandotrader
$AVR These results were achieved in a symptomatic and clinically complex population. At baseline, 61% of patients were in NYHA class III/IV, the mean STS-PROM score was 4.7 ± 4.0%, and the cohort included heavy calcification and bicuspid anatomy (9%). Patients were pooled from the EMBARK and early feasibility studies (EFS) conducted in the United States and Europe; previously, 30-day data from this cohort were presented at PCR London Valves 2025.
1

Advertisement|Remove ads.